Together, we boldly transform insights into treatments benefiting those who need them when they need them. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. "Today's verdict confirms that the 2010 settlement agreement between Endo and Impax was procompetitive and enabled Impax to come to market with its generic version of Opana® ER years earlier than otherwise would have been permitted."Įndo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Maletta, Endo's Executive Vice President, Chief Legal Officer and Company Secretary. "Endo is very pleased with the jury's verdict and is grateful for its careful deliberation," said Matthew J.
#Endo pharmaceuticals stock quote trial#
A trial of all plaintiffs' claims began in June and concluded today with a verdict in favor of Endo on all counts. (now Amneal Pharmaceuticals, Inc.) (Impax) violated the antitrust laws.
Plaintiffs in the cases alleged, among other things, that the terms of a 2010 patent settlement agreement between Endo and Impax Laboratories, Inc. As Endo previously disclosed, it has been involved since 2014 in various legal proceedings filed by multiple plaintiffs, including classes of direct and indirect purchasers, which have been consolidated in the United States District Court for the Northern District of Illinois under the caption In re Opana® ER Antitrust Litigation.
0 kommentar(er)
